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Protection from reinfection in “Candidatus
Mycoplasma turicensis”-infected cats and
characterization of the immune response
Marilisa Novacco1*, Felicitas S Boretti2, Marco Franchini3, Barbara Riond1, Marina L Meli1
and Regina Hofmann-Lehmann1
Abstract
“Candidatus Mycoplasma turicensis” (CMt) is a hemoplasma species of felids. Recent evidence has shown that cats
that overcome bacteremia may be protected from reinfection. The purposes of this study were to (1) re-inoculate
ostensibly recovered cats, (2) evaluate the immune response and (3) assess CMt tissue loads. Fifteen specified
pathogen-free cats were subcutaneously inoculated with CMt: 10 cats (group A) had previously undergone
bacteremia and recovered, and 5 naïve cats (group B) served as controls. CMt infections were monitored by
real-time PCR using blood and tissue, and the humoral immune response was assessed using DnaK ELISA. Cytokine
mRNA expression levels were measured by real-time PCR, and lymphocyte subsets were detected by flow
cytometry. The cats in group A were protected from reinfection (no detectable bacteremia) and showed a transient
decrease in antibodies. Eosinophilia was noted in cats from group A. The cats from group B became PCR-positive
and seroconverted. All of the tissues analyzed from the cats in group B but none of the tissues analyzed from the
cats in group A were CMt PCR-positive. Significant changes were observed in the expression of tumor necrosis
factor-α, interferon-γ, interleukin-4 and the Th2/Th1 ratio in both groups. The cats from group A occasionally
showed higher numbers of CD4+, CD8+, CD4+CD25+ and CD5+MHCII+ T lymphocytes than the control cats. In
conclusion, this study describes, for the first time, the occurrence of immunological protection within the same
hemoplasma species. Furthermore, the immune response during CMt infections appeared to be skewed toward the
Th2 type.
Introduction
“Candidatus Mycoplasma turicensis” (CMt) was first
isolated in a cat with hemolytic anemia [1]. During the
acute phase of the infection, CMt can induce mild to
moderate anemia in experimentally infected domestic
cats but anemia does not always result [1]. The patho-
genic potential of the different feline haemoplasma
species varies and co-factors, such as immunosuppres-
sion, co-infections with other hemoplasma species or
retroviral infections, may increase the severity of the
disease [2]. CMt has been reported worldwide with
different prevalence. In Europe the prevalence ranges
from 1 to 2.3% [2]. The route of transmission is still
not completely understood, but blood sucking arthro-
pods are suspected to play a role [3-6]. Aggressive inter-
actions between cats as well as blood transfusions have
also been associated with transmission of hemotropic
mycoplasma [7,8]. In experimental transmission studies,
the intraperitoneal, intravenous and subcutaneous inocu-
lation of infectious blood was successfully used to induce
infection [9-11]. Experimental transmission studies have
shown that CMt-infected animals develop bacteremia
within 14 to 45 days post-exposure and remain PCR-
positive for 10 to 21 weeks after inoculation [1,11].
Infected cats show evidence of seroconversion 10 to
47 days after exposure, and their antibody levels increase
during the bacteremia [11-13]. Recently, we reported a
long-term follow-up of CMt-infected cats using a newly
developed Mycoplasma haemofelis (Mhf ) DnaK enzyme-
linked immunosorbent assay (ELISA) [12-14]. The assay
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has been applied to quantify anti-DnaK antibodies in cat
experimentally infected with Mhf, “Candidatus Myco-
plasma haemominutum” and CMt [13-16]. Interestingly,
intermediate to high levels of antibodies were observed in
cats that had recovered from CMt bacteremia for more
than 1 year after inoculation [12]. The cats in this study
were CMt-negative in their blood samples as determined
by real-time TaqManW PCR, but low bacterial copy num-
bers were detected in some of their tissues [12]. A prelim-
inary experiment indicated that CMt-seropositive cats
may be protected from a peak bacteremia subsequent to a
repeated challenge with CMt; however, this study lacked
the necessary control group [13]. The aim of the present
study was to confirm and investigate this potential im-
munological protection during a subsequent CMt chal-
lenge under well-controlled experimental conditions. In
addition, to characterize the immune response, antibody
levels were assessed using Mhf DnaK ELISA, and cytokine
mRNA profiles were measured by real-time TaqmanW PCR.
Furthermore, leukocyte subsets were monitored by flow
cytometry.
Materials and methods
Animals and experimental design
Fifteen adult, age-matched, neutered, male, specified
pathogen-free (SPF) cats from Liberty Research, Inc.
(Waverly, New York, USA) were used for this study. The
SPF status was confirmed prior to this study [11]. The
cats were housed in groups in a confined university facil-
ity under ethologically and hygienically ideal conditions
[17]. All experiments were approved by the veterinary
office of the canton Zurich (TVB 159/2010) and were
conducted in accordance with Swiss laws. Ten cats
(group A) were subcutaneously infected with CMt-
positive blood 26–31 months prior to this study, as
previously described [11]. The cats in group A had under-
gone a previous experimental CMt infection and recov-
ered from CMt bacteremia: they were PCR-negative for
CMt in the peripheral blood, and 9 of the 10 cats
were serologically positive for a well-recognized hemo-
plasma antigen, Mhf DnaK. Long-term follow-up of the
cats in group A was conducted, as previously reported
[12]. Five cats (group B) that had never been exposed to
CMt prior to this study served as naïve controls for the in-
oculation of CMt. The cats in group B were confirmed
to be PCR-negative for feline hemoplasmas and sero-
negative for Mhf DnaK. All 15 cats were inoculated
with CMt by subcutaneous injection of 10 μL of
blood containing 1 × 103 copies of CMt diluted with
90 μL phosphate buffered saline (PBS), as previously
described [11]. Ethylenediaminetetraacetic acid (EDTA)-
anticoagulated blood and plasma samples were collected
from all cats prior to the CMt challenge, and blood sam-
ples were collected on days 1, 2, 3 and 7 and weekly
thereafter for hematology, PCR analysis and serology. The
cats were monitored for 83 days post-inoculation (pi).
Samples for PCR and serology were stored at −80°C
within 2 h after collection. Complete hemograms were
performed using a Sysmex XT-2000iV (Sysmex Corpor-
ation, Kobe, Japan) that had been previously evaluated for
feline blood samples [18]. Packed cell volume (PCV)
values of 33 - 45% (5 - 95% quantiles of the reference
range) were considered to be within the reference range,
and anemia was defined as having a PCV < 33%. For white
blood cell differential analysis, microscopic blood smears
were evaluated. Two blood smears were stained with
a modified Wright stain using an automated staining
instrument for each blood sample (Hema Tek 1000,
Bayer AG, Zurich, Switzerland). Two technicians with
more than 10 years of experience in veterinary hematology
independently differentiated 100 cells per smear. Fol-
lowing the conclusion of this study, 5 cats in group
A were adopted, and all other cats remained at the
facility.
Tissue sample collection
To determine whether CMt bacteria were present in the
organs, tissue samples were collected under short-duration
general anesthesia and analgesia by fine needle aspiration
(FNA), as previously described [12]. Tissues were collected
on day 30 pi from the cats in group A and on day 31 pi
from the cats in group B. Tissue samples were collected
from the kidney, liver and salivary glands. In addition, sal-
iva swabs and bone marrow aspirates were collected. Bone
marrow aspirates were collected from the proximal hu-
merus under short-duration general anesthesia using a pre-
viously described protocol [11].
Nucleic acid extraction
Total nucleic acid (TNA) was purified from 100 μL of
EDTA-anticoagulated blood using the MagNaPure LC
Total Nucleic Acid Isolation Kit (Roche Diagnostics,
Rotkreuz, Switzerland). DNA was purified from the
tissue samples using the DNA Micro Kit (Qiagen,
Hombrechtikon, Switzerland). DNA from the bone mar-
row samples was purified using the DNA Blood and Tis-
sue kit (Qiagen) according to the manufacturer's
instructions. For each batch of extractions, negative con-
trols consisting of 200 μL of phosphate-buffered saline
were concurrently prepared to monitor for cross-
contamination.
Quantitative TaqManW real-time PCR assays
All blood and tissue samples were tested in triplicate by
real-time TaqManW PCR for the presence and bacterial load
of CMt, as previously described [1]. In addition, a TaqManW
real-time PCR reaction amplifying the pseudogene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [19]
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was included for all tissue samples to confirm the presence
of amplifiable DNA and the absence of significant PCR
inhibitors [12]. Only samples with more than 5 000 copies
of GAPDH/PCR reaction were considered acceptable, and
the DNA extraction was repeated for samples that pro-
duced insufficient copies. CMt tissue loads were normal-
ized by dividing the CMt copy number by the GAPDH
copy number [12,20]. In each real-time PCR reaction, a
positive control and 2 negative controls consisting of nu-
cleic acid-free water were included.
Serology
Antibodies against the Mhf DnaK protein were detected
and quantified in naïve and serologically positive cats
after CMt inoculation using an ELISA assay, as described
[14]. The serum was diluted by 1:100 in wells, and 50 ng
of recombinant protein per well was used. Wells contain-
ing antigen without serum served as blanks, and wells
containing pre-infection serum samples served as nega-
tive controls. The ELISA signal-to-noise ratio was calcu-
lated by dividing the post-infection absorbance values by
the pre-infection absorbance values for each individual
cat, as previously described [14]. An ELISA signal-to-
noise ratio of ≥ 1.5 was considered positive.
RNA isolation and cDNA synthesis
Blood samples for cytokine transcriptional analysis were
collected on days 1, 3, 7, 14, 21, 28 and 35 pi from all cats
in both groups. One hundred microliters of EDTA-
anticoagulated blood was collected and mixed immediately
with 300 μL of mRNA lysis buffer (mRNA Isolation Kit I,
Roche Diagnostics, Rotkreuz, Switzerland). The samples
were stored at −80°C within 1 h of collection. mRNA was
purified using the mRNA Isolation Kit I and a MagNA
Pure LC instrument (Roche Diagnostics) according to the
manufacturer's instructions. For all extractions, negative
controls consisting of 100 μL of phosphate buffered saline
were prepared alongside each batch to monitor for cross-
contamination. mRNA was eluted in 25 μL of elution buf-
fer and was stored at −80°C until further use. First-strand
cDNA was synthesized using the High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems, Rotkreuz,
Switzerland) according to the manufacturer's instructions.
For each mRNA sample, cDNA was synthesized in dupli-
cate and then pooled. The cDNA samples were stored at
−20°C until used in the PCR measurements.
Real-time TaqManW PCR for quantification of cytokine
expression
Real-time TaqManW PCR was used for the relative quan-
tification of feline interferon-γ (IFN-γ), interleukin (IL)
4, 6, 10 and 12 and tumor necrosis factor-α (TNF-α).
The PCR assays used in this study have been described
elsewhere [19,21,22]. V-abl Abelson murine leukemia
viral oncogene homolog (ABL) and zeta polypeptide
(YWHAZ) transcription levels served as reference genes
for normalization, and these genes were quantified by
real-time PCR, as previously described [23]. PCR assays
were performed using a Rotor-Gene 6000 real-time
rotary analyzer (Corbett, Mortlake, Australia). Negative
and positive controls were included in each PCR run.
The calculation of mRNA expression levels was per-
formed using GeNorm version 3.5 [24].
Preparation and labeling of lymphocytes and flow
cytometry
EDTA-anticoagulated blood samples were collected from
the cats in groups A and B before CMt inoculation and on
days 1, 2, 3 and 7 and weekly thereafter until day 56 pi.
The blood samples were processed within 1 h after collec-
tion. Tubes were gently rotated end-over-end for 5 min at
room temperature before cell preparation. Then, the
blood samples were divided into 100 μL aliquots and
placed in 5 mL Falcon polystyrene tubes (BD Biosciences,
Allschwil, Switzerland). The aliquots were incubated at
4°C in the dark for 30 min with one of the following anti-
body combinations: 1) a fluoresceinisothiocyanate (FITC)-
conjugated mouse anti-feline CD5 antibody (f43, Southern
Biotech, Allschwil, Switzerland) recognizing T lympho-
cytes [25] and an unconjugated mouse anti-feline MHCII
antibody (H34A, VMRD); 2) an R-phycoerythrin (RPE)-
conjugated mouse anti-feline CD4 antibody (Vpg34, AbD
serotec, Düsseldorf, Germany) and a fluoresceinisothio-
cyanate (FITC)-conjugated mouse anti-feline CD25 anti-
body (kindly provided by MB Tompkins, North Carolina
State University, USA); 3) an unconjugated mouse
anti-feline CD8 antibody (FT2, Southern Biotech) and
a peridinin chlorophyll-a protein (PerCP)-conjugated
rat anti-mouse CD45R/B220 antibody (RA3-6B2, BD
Bioscience). The antibodies were diluted as recom-
mended by the manufacturer, and an aliquot of blood
from each cat was used unstained as an isotype-
matched control antibody. After incubation with the
antibody, the samples were treated with 2 mL of Tris-
NH4Cl (pH 7.2) for 7–8 min to selectively lyse the red
blood cells. The samples were centrifuged at 600 × g
for 10 min to pellet the leukocytes. The leukocyte pel-
let was incubated with secondary antibodies or with
PBS containing 2% fetal calf serum (Gibco Life Tech-
nologies, Basel, Switzerland) at room temperature for
20 min. Allophycocyanin (APC)-conjugated mouse
IgG1 anti-CD8 antibody (BD Pharmingen) and an
RPE-goat anti-mouse IgG2b MHCII antibody (Southern
Biotech) were used for staining leukocytes. All antibodies
used in the current study have been previously used in
feline species [26,27]. After antibody incubation, the cells
were washed with PBS containing 2% fetal calf serum
and were centrifuged at 600 × g for 10 min to pellet the
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leukocytes. The cells were resuspended in 250 μL of PBS
containing 2% fetal calf serum and were immediately
subjected to flow cytometry. The cells were enumerated
and differentiated using the BD FACSCalibur™ platform
(Becton Dickinson, Allschwil, Switzerland) and the Cell-
QuestPro™ software. Gates representing lymphocytes
were set based on forward versus side scatter, and 10 000
events were acquired for each sample. Each lymphocyte
subset was calculated by multiplying the absolute
lymphocyte number (determined by the complete blood
cell count) by the subset percentage (expressed as the
percentage of lymphocytes determined by flow analysis),
as previously described [28]. The data were analyzed
using FlowJo software (Tree Star, Olten, Switzerland).
Statistics
Statistical analyses were performed using GraphPad
Prism for Windows version 3.0 (GraphPad software, San
Diego, CA, USA). The Mann–Whitney U-test (PMWU)
was used to compare parameters between groups, and
the Wilcoxon signed rank test (PWilcoxon) was applied for
paired analyses. Friedman’s test (PFriedman), followed by
Dunn’s post-test (PDunns), was used to analyze the para-
meters over time. Correlation analyses were performed
using Spearman’s rank order correlation coefficient test
(rs). P-values < 0.05 were considered to be significant.
Results
Clinical and laboratory parameters
None of the cats in groups A or B developed clinical
signs indicative of a hemoplasma infection (e.g., pallor,
lethargy, fever or weight loss). Six out of the 10 cats
from group A showed intermittent PCV values below
the reference range (PCV < 33%, 5% quantile) starting at
day 1 pi, and the lowest PCV value observed in group A
was 27%. All five cats in group B showed PCV values <
33% during the observation period; however, 2 cats from
group B had PCV values of 30% and 32% on day 0. The
lowest observed PCV value in group B was 22%. The
cats from group B had significantly lower PCV values
than the cats from group A after the onset of bacteremia
(days 35, 70 and 83 pi, PMWU < 0.05).
Five out of the 10 cats from group A showed
leukocytosis (> 12 800/μL, 95% quantile) on occasion
throughout the observation period. Additionally, 2 cats
from group A (cats FHX4 and FHX5) demonstrated
increased leukocyte counts during the entire study (up
to 21 400/μL), including on day 0. The cats from group
A showed higher leukocyte counts when compared with
the cats from group B on days 0, 1, 7, 14, 21, 28, 35, 42,
63 and 70 (PMWU < 0.05).
Lymphocyte counts were significantly higher in the
cats from group A when compared with the cats from
group B on day 28 pi (PMWU = 0.0047). Overall, 3 cats
from group A demonstrated lymphocyte counts above
the reference range (6 000/μL, 95% quantile), and 2 of
them (cats FHX4 and FHX5) showed consistently higher
lymphocyte counts throughout the observation period,
including day 0, which is indicative of lymphocytosis (up
to 10 070/μL).
Differences between groups A and B were also noted
in neutrophil and monocyte counts at different time
points of the experiment, but the majority of the values
remained within the reference range (46 - 678/μL and 2
315–10 011/μL, 5 - 95% quantiles, for monocytes and
neutrophils, respectively). The cats from group A
showed higher neutrophil counts when compared with
the cats from group B on days 0, 1, 7, 21, 35, 42, 63 and
70 (PMWU < 0.05). Higher monocytes counts were found
in cats from group B on days 35 and 42 pi compared to
the cats from group A.
In contrast, eosinophilia (values > 600/μL, 95% quan-
tile) was detected in the cats from group A, and 7 out of
the 10 cats from group A demonstrated eosinophilia
throughout the entire study, including day 0 (up to
2 290/μL). A significant difference in eosinophil num-
bers was detected between groups A and B from day 28
pi until the end of the observation period (PMWU < 0.05);
this trend was also present, albeit not quite significant,
on days 7, 14 and 21 pi (PMWU = 0.0553).
Protection from CMt challenge in ostensibly recovered
cats
The cats from group A remained PCR-negative in blood
throughout the entire study (Figure 1A). The cats from
group B became PCR-positive after an average of 19 days
(range: 17–21 days pi) with peak blood loads ranging
from 104 - 105 copies/mL of blood between 28–35 days
pi (Figure 1B). In all tissue samples, a sufficient amount
of amplifiable DNA and the absence of PCR inhibitors
were confirmed using GAPDH TaqManW real-time PCR.
All five cats from group B showed detectable CMt tissue
loads (Table 1), whereas no CMt DNA was detected in
any of the tissue samples analyzed for the cats in group
A (Table 1).
Humoral immune response
At the beginning of this study, 9 out of the 10 cats from
group A were seropositive (Figure 2A). One cat (cat
FHT2, group A) showed a signal-to-noise ratio ≤ 1.5 by
ELISA and was therefore considered seronegative
(Figure 2A). However, this cat also showed protection
from CMt reinfection (Figure 1A). Remarkably, a signifi-
cant transient decrease in antibodies was observed in the
cats from group A on day 1 pi (PWilcoxon = 0.0098), which
was followed by a significant increase in antibody levels
by day 2 pi (PWilcoxon = 0.0059) (Figure 2A). No signifi-
cant differences in antibody levels were detected over
Novacco et al. Veterinary Research 2012, 43:82 Page 4 of 13
http://www.veterinaryresearch.org/content/43/1/82
time in the cats from group A. The cats from group B
were seronegative prior to CMt inoculation and became
seropositive between 28 and 35 days pi (Figure 2B). The
cats from group B remained seropositive until the end of
the observation period.
Evaluation of the cytokine response
CMt inoculation induced an approximately 2.5-fold
upregulation of TNF-α within the first week in the cats
from groups A and B (PWilcoxon = 0.0020 and PWilcoxon =
0.0625 for groups A and B, respectively; Figure 3A).
However, the TNF-α levels returned to basal values
(level before CMt inoculation) within 14 days pi in both
groups. No significant differences in TNF-α levels were
detected between groups A and B.
In the cats from group A, IFN-γ expression levels
were statistically significantly higher at day 3 com-
pared to day 35 pi (PWilcoxon = 0.0039, Figure 3B).
The cats in group B showed a nearly 2.5-fold upre-
gulation of IFN-γ expression from day 1 to day 7 pi
(Figure 3B), which resulted in significantly higher
IFN-γ levels in the cats from group B compared to
the cats from group A on day 7 (PMWU = 0.0400).
Thereafter, the IFN-γ levels decreased significantly
(PWilcoxon = 0.01) to slightly below basal levels by day
14 and day 21 pi in group B.
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Figure 1 CMt blood loads in fifteen SPF cats after CMt inoculation. Cats in groups A (A) and B (B) were inoculated subcutaneously at day 0
and were monitored for 83 days. CMt blood loads (y-axes) are expressed as the log copy numbers per mL of blood. The cats in group A
showed no detectable bacteremia upon CMt inoculation, whereas the cats in group B became CMt PCR-positive after an average of 19 days
(range: 17–21 days).
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IL-4 expression levels changed significantly over time
in both groups (PFriedman < 0.001). The cats from group
A showed increased IL-4 levels on day 14 (approxi-
mately 20-fold upregulation), but this trend was only
transient, with significantly lower levels in comparison
to group B on days 21 (Figure 3C; PMWU= 0.0177) and 35
(Figure 3C; PMWU= 0.0101). The IL-4 expression levels in
group A were statistically significantly higher on days 14,
21, 28 and 35 pi when compared with the IL-4 levels from
day 1 (PWilcoxon < 0.05) and remained increased by approxi-
mately 10-fold until the end of the observation period. The
cats from group B showed an increase in IL-4 expression
levels after day 7 and the IL-4 levels in group B cats con-
tinuously increased until day 35 pi. IL-4 levels in group B
cats were statistically significantly higher at day 35 pi com-
pared to days 1, 3 and 7 pi (PDunns < 0.05; Figure 3C), peak-
ing at an approximately 30-fold higher level of IL-4 when
compared with the basal levels (Figure 3C). In group B, the
IL-4 levels correlated significantly with the CMt bacterial
blood load (rs = 0.82; P < 0.0001).
No significant differences were found in IL-12 levels
after CMt inoculation between the two groups through-
out the observation period (Figure 3D). We further cal-
culated the ratio of IL-4 to IL-12 expression levels as a
surrogate marker for the T helper 2 (Th2)/T helper 1
(Th1) ratio. Both groups of cats showed an increase in
their Th2/Th1 ratio between days 7 and 14 pi
(Figure 3E; PWilcoxon = 0.0078 and PWilcoxon = 0.0625 in
groups A and B, respectively). The cats from group A
showed a significantly higher Th2/Th1 ratio on day 14
than the cats from group B (Figure 3E; PMWU = 0.0031),
whereas the cats from group B showed a higher Th2/
Th1 ratio than the cats from group A on day 35 pi
(Figure 3E; PMWU = 0.0025). When Th2/Th1 ratios were
calculated using IL-4 and IFN-γ as the surrogate mar-
kers, similar results were obtained: an increase in the
Th2/Th1 ratio in both groups was observed between day
7 and day 14 pi (Figure 3F; PWilcoxon = 0.0078 and PWil-
coxon = 0.0625 in groups A and B, respectively). In
addition, prior to the observed increase between days 7
and 14 pi, the Th2/Th1 ratio decreased from day 1 to day
7 in group B (Figure 3F; PWilcoxon = 0.0625), while no dif-
ferences were noted in group A.
IL-10 expression levels changed significantly over time
in cats from group A (Figure 3G; PFriedman = 0.0138). In
the cats from group A, IL-10 expression levels were sta-
tistically significantly higher at day 35 compared to days
1 and 3 pi (PDunns < 0.05, Figure 3G). No significant dif-
ferences in IL-10 levels over time were detected in group
B cats. IL-10 expression levels in the cats from group A
were significantly lower compared to the cats from
group B on days 28 and 35 (PMWU = 0.0047). The IL-6
expression levels were below the detection limit of real-
time PCR in 41 out of 105 samples tested (data not
shown). Therefore, the IL-6 levels were excluded from
the statistical analysis.
Leukocyte subsets after CMt inoculation
No significant differences in any of the tested cell sub-
sets were detected between groups A and B on day 0.
After CMt inoculation, significant changes in the CD4+
T cell counts were detected in groups A and B (PFriedman <
0.001). In particular, the cats from group A showed a sta-
tistically significant decrease in CD4+ T cells from day 2 to
Table 1 CMt tissue loads (copies/106 cells) determined by real-time TaqmanW PCR in tissue samples collected at days
30 and 31 pi for cats in groups A and B
Group Cat Kidney Liver Salivary gland Bone marrow Saliva swab
A FIA1 - - - - -
FIA2 - - - - -
KHR1 - - - - -
KHR2 - - - - -
FHS1 - - - - -
FHS2 - - - - -
FHT1 - - - - -
FHT2 - - - - -
FHX4 - - - - -
FHX5 - - - - -
B M3 70 684 169 25 140 680 319 61
NFN1 376 2 555 298 501 6 066 26
NFP1 576 387 13 871 244 306 402
NFQ4 12 801 10 568 6 039 2 080 495
NFS2 15 138 40 981 27 389 738 300 0
- = CMt tissue loads were below the detection limit of PCR [7].
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day 14 pi (Figure 4A; PDunns < 0.05). This decrease was fol-
lowed by an increase in CD4+ cells from day 35 to day 56
(Figure 4A; PDunns < 0.05). The cats from group B showed
a statistically significant decrease in CD4+ cells from day 2
to day 42 (Figure 4A; PDunns < 0.05) followed by a signifi-
cant increase from day 42 to day 49 pi (Figure 4A; PDunns
< 0.05). The cats from group A showed higher CD4+ T cell
counts when compared with the cats from group B on
days 1, 2, 7, 14, 28, 35 and 42 (Figure 4A; PMWU < 0.04).
No statistically significant changes over time were noted
in the CD8+ T cell populations during the observation
period in group A or B. However, the cats from group A
showed significantly higher numbers of CD8+ T cells when
compared with cats from group B on days 1, 7 and 28 pi
(Figure 4B; PMWU< 0.05). In addition, we calculated the CD4
+
/CD8+ ratio (Figure 4C) and found that it changed signifi-
cantly during the observation period in cats from groups A
and B (PFriedman < 0.001). Both groups showed a decrease in
the CD4+/CD8+ ratio between day 28 and day 35 pi; however,
this decrease was only significant in group B (Figure 4C;
PDunns < 0.05). We also observed a subsequent increase in the
CD4+/CD8+ ratio between day 35 and day 42, which was sig-
nificant in group A (PDunns < 0.001; Figure 4C). No statistical
differences were noted between groups A and B.
Significant changes in the CD4+CD25+ T cell counts
were detected during the observation period in both
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Figure 2 Humoral immune response to Mhf DnaK after CMt exposure. Cats in groups A (A) and B (B) were inoculated subcutaneously with
CMt on day 0 and were monitored for 83 days. Antibody levels are shown as signal-to-noise ratios (y-axes). The cats in group A showed a
significant transient decrease in antibody levels 1 day after inoculation, whereas seroconversion was detected in the cats from group B between
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groups (PFriedman < 0.001). In particular, two significant
decreases in the CD4+CD25+ cell population were
detected in the cats from group A on day 35 and day 56
pi (Figure 4D; PDunns < 0.05). The first decrease in
CD4+CD25+ T cells was followed by a significant in-
crease between day 35 and day 42 pi (Figure 4D; PDunns
< 0.01). The cats from group B showed a statistically sig-
nificant decrease in the CD4+CD25+ counts on day 28 pi
(Figure 4D; PDunns < 0.05), which was followed by a sig-
nificant increase on day 49 pi when compared with day
28 pi (Figure 4D; PDunns < 0.05). Higher CD4
+CD25+ T
cell counts were also observed on days 28 and 42 pi in
the cats from group A relative to the cats from group B
(Figure 4D; PMWU < 0.006).
Significant changes in CD5+MHCII+ T cells were
found in groups A and B over time (PFriedman < 0.001).
The cats from group A demonstrated a statistically sig-
nificant lower CD5+MHCII+ T cell levels at days 42, 49
and 56, respectively, compared to day 3 pi (Figure 4E;
PDunns < 0.05). A transient decrease in CD5
+MHCII+ T
cell levels was also noted in the cats from group B on
day 28 and day 42 relative to day 2 pi (Figure 4E). Sig-
nificantly higher CD5+MHCII+ T cell levels were noted
in the cats from group A relative to the cats from group
B on days 1, 14 and 28 pi (Figure 4E; PMWU < 0.04).
A significant decrease in B220+ cell levels was detected
in the cats from group A on days 35, 42 and 56 relative
to day 3 pi (Figure 4F; PDunns < 0.05). No significant
changes in B220+ cell levels were noted in the cats from
group B, and no statistically significant changes were
noted in B220+ cell levels between groups A and B.
Discussion
The present study describes, for the first time, the im-
munological protection from reinfection in cats that
overcome CMt bacteremia under well-controlled experi-
mental conditions. Cats that had ostensibly overcome
the acute phase of CMt infection without antibiotic
treatment were re-inoculated with CMt and showed pro-
tection from a second bacteremia. In contrast, the naïve
control cats became PCR-positive in blood and tissue
samples after CMt inoculation. The mechanisms
involved in the protection of these cats have not been
completely elucidated by our study, but our evidence
suggests a significant role of the humoral and cellular
immune responses in this protection.
We evaluated the humoral immune response to CMt
to detect possible changes in antibody levels after CMt
inoculation. The cats that had overcome a previous
bacteremia showed intermediate to high levels of anti-
bodies before CMt challenge. A boost in CMt-specific
antibodies could have been expected due to the repeated
exposure; however, the majority of cats from group A
showed a significant transient decrease in antibodies
upon CMt reinfection. A similar decrease in antibody
was recently described in a preliminary study investigat-
ing repeated CMt exposure [13]. In that study, the
authors speculated that the decrease in serum antibodies
may be related to the binding of specific free antibodies
to the inoculated antigens [13]. Remarkably, one cat in
the group of CMt recovered cats was seronegative based
on our definition (ELISA signal-to-noise ratio ≤ 1.5);
however, this cat maintained protection against reinfec-
tion. This observation suggests that specific antibodies
against Mhf DnaK are not the sole protective mechanism
against reinfection in these cats. Mhf DnaK is a hemo-
plasma antigen that is largely used in experimental stud-
ies to detect seroconversion after hemoplasma infection
[12,13,15,16]. Other antigens have been recognized in
blood samples from Mhf-infected cats [29,30], but their
immunological potential is unknown. The entire feline
hemoplasma genome has been recently sequenced
[31,32]; thus, information regarding additional antigens
may soon become available. In serological assays, the
combination of different antigens should be considered
for a better understanding of the kinetics of the humoral
immune response during hemoplasma infection.
In this study, we demonstrated that CMt was present
in all analyzed tissues of the naïve control cats upon
acute infection, as high tissue loads were found, particu-
larly in the bone marrow. In contrast, the ostensibly
recovered cats tested PCR-negative in all tissues ana-
lyzed, including the bone marrow. Thus, it appears that
the cats were not only protected from bacteremia but
were also sufficiently protected from recurrent tissue se-
questration to prevent detection based on repeated real-
time PCR measurements in the analyzed tissues.
To further characterize the immune response after
CMt exposure in naïve control cats and recovered cats,
we quantified different cytokine expression levels. Imme-
diately after CMt inoculation, all cats showed a signifi-
cant increase in TNF-α secretion. This cytokine is the
(See figure on previous page.)
Figure 3 Relative expression levels of TNF-α (A), IFN-γ (B), IL-4 (C), IL-12 (D) and IL-10 (G) after CMt inoculation on day 0 in cats from
group A (black squares) and group B (open squares). The Th2/Th1 ratio is expressed as the IL-4/IL-12 ratio (E) and the IL-4/IFN-γ ratio (F).
Cytokine mRNA expression levels were measured by real-time TaqmanW PCR and were normalized to the expression levels of two housekeeping
genes (ABL and YWHAZ) at each time point. The values shown represent the mean and standard deviation for each group of cats. The arrow
indicates the onset of bacteremia and the gray box indicates the peak bacteremia for the cats in group B. Relative expression levels were tested
for statistical differences between groups by the Mann–Whitney U-test (asterisks indicate statistically significant differences; P < 0.05).
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principal mediator of the acute inflammatory response
[33]. TNF-α is produced by activated mononuclear pha-
gocytes, and the function of TNF-α is to stimulate the
recruitment of neutrophils and monocytes to sites of in-
fection [33]. We suspect that the subcutaneous inocula-
tion of CMt stimulated the release of TNF-α, and it was
indeed detected in acutely infected as well as in re-
exposed cats.
The Th1/Th2 paradigm has been previously described
in cats [34]. Thus, we were able to select cytokines spe-
cific for each type of T helper response for the cats in
this study. Th1 cells mainly mediate immune responses
against intracellular pathogens, whereas Th2 cells are
mainly involved in host defense responses against extra-
cellular pathogens and atopic diseases [35]. IL-4 stimu-
lates the expansion of B cells and Th2-associated cells,
inhibiting the proliferation of Th1 cells [36]. On the
other hand, IFN-γ is secreted by Th1 cells, inducing
antimicrobial activity in macrophages [37]. The cats
acutely infected with CMt (naïve control cats) showed
an early transient increase in IFN-γ expression (Th1
cytokine) that peaked at day 7 after CMt inoculation. In
contrast, the cats that had recovered from previous CMt
bacteremia did not show an early increase in IFN-γ
expression but rather showed a pronounced increase in
IL-4 expression (Th2 cytokine) at day 14 pi and prior to
the time point corresponding to bacteremia in acutely
infected cats. Thus, in the CMt recovered cats, protec-
tion from reinfection was associated with an early and
pronounced Th2 response, whereas the acutely infected
cats responded to CMt challenge with an initial Th1 re-
sponse and a delayed Th2 response. A switch from a
Th1 to a Th2 response in acutely infected cats was
observed based on the evolution of the IL-4/IFN-γ
ratios. An initial decrease in the ratio of IL-4/IFN-γ was
followed by an increase, which was in turn followed by
bacteremia. In contrast, the CMt recovered cats did not
display skewed Th1/Th2 ratios based on either the IL-4/
IFN-γ ratio or the IL-4/IL-12 ratio. Only after the onset
of bacteremia were IL-4 levels higher in the acutely
infected cats when compared with the CMt recovered
cats, and the IL-4 levels were correlated with the bacter-
ial load. Thus, an early Th2 response prior to the onset
of bacteremia appears to be beneficial to the protection
from CMt reinfection, while a delayed Th2 response
seemed to be generated in response to the underlying
bacteremia.
Interestingly and in agreement with the trend in Th2
responses, we detected a constant eosinophilia during
CMt infection, which was particularly evident in the
CMt recovered cats. Eosinophilia is a hallmark of a pre-
dominance of the Th2 response [38,39]. The recruitment
of eosinophils, although usually associated with parasitic
and allergic inflammation, can also be associated with
certain bacterial infections [40]. Eosinophilia has been
previously reported during feline hemoplasma infections
but was not considered clinically relevant [41,42]. In
addition, a previous study reported an association be-
tween eosinophilia and latent Haemobartonella canis in-
fection [43]. In the context of observations by other
researchers, our results may suggest that CMt infection
leads to an upregulation of Th2 cell populations, which
in turn stimulates the recruitment of eosinophils.
Different markers were used to analyze the lymphocyte
subsets by flow cytometry after CMt inoculation. The
cats that had recovered from previous bacteremia
showed higher CD4+ T cell levels when compared with
acutely infected cats at several time points after the CMt
inoculation. As mentioned earlier in this discussion, our
results suggest that the Th2 differentiation of CD4+ T
cells occurs during CMt infection to efficiently combat
CMt. The Th2 response is characterized by B cell activa-
tion and proliferation [37]. Thus, the immune system of
CMt recovered cats appears to immediately recognize
CMt antigens, and this results in rapid activation of the
appropriate T helper cells. T helper cells appear to assist
CMt recovered cats to fight subsequent CMt infections
and prevent bacteremia by activating secondary mechan-
isms (e.g., antibody production). Additionally, the activa-
tion of CD4+ T cells was most likely responsible for the
recruitment of eosinophils [44].
CD4+CD25+ T cells represent a subpopulation of
CD4+ T cells commonly known as regulatory T cells
[45]. This subset of cells suppresses the proliferation
and cytokine secretion of other T cell populations and
suppresses the activation of self-reacting CD4+ and
CD8+ T cells [46]. Additionally, regulatory T cells may
influence the functional immunity of cats during mi-
crobial infection to suppress the immune response to
pathogens [47]. For this reason, CD4+CD25+ T cells
were monitored during our study to understand their
role during infection. CD4+CD25+ T cell levels were
higher in the CMt recovered cats when compared with
the acutely infected cats following the onset of
bacteremia. The downregulation of the immune re-
sponse induced by regulatory T cells may have pro-
moted the persistence of the CMt infection and may
have been instrumental in the establishment of the
CMt carrier state. The number of regulatory T cells
decreased at peak bacteremia in the acutely infected
cats, which may be related to the role of these cells in
regulating the immune response. With a decreased
number of regulatory T cells, the acutely infected cats
showed downregulation of the suppressive function of
these cells, which in turn was most likely beneficial for
fighting the CMt infection.
Some T cell activation marker levels were higher in the
cats that had overcome previous bacteremia than in the
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acutely infected cats at various time points during
the observation period. This could be related to the
increased lymphocyte counts detected in the CMt
recovered cats, as the lymphocytosis was probably
due to chronic CMt antigenic stimulation. A similar
phenomenon was identified during a cross-protection
study in feline hemoplasmas (unpublished observa-
tions, Baumann J, Novacco M, Hofmann-Lehmann R),
whereby cats chronically infected with CMt showed
significant antigenic stimulation, which led to an in-
crease in γ-globulin (unpublished observations, Baumann J,
Novacco M, Hofmann-Lehmann R).
In conclusion, our data indicate that cats that over-
come CMt bacteremia possess a persistent immune
response skewed towards the Th2 type, which is asso-
ciated with protection from reinfection with CMt.
Further studies are required to better understand the
immunological mechanisms involved in this protec-
tion. Characterization of the protective immune re-
sponse against hemoplasmas is an initial step toward
the development of effective vaccines against these
types of infections.
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